XDWL:F:F-db x-trackers MSCI World UCITS DR 1D (EUR)

ETF | Others |

Last Closing

USD 87.51

Change

0.00 (0.00)%

Market Cap

USD 1.13B

Volume

2.05K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
PRAJ:F Amundi Index Solutions - Amund..

N/A

USD 139.20B
UIM5:F UBS (Lux) Fund Solutions - MSC..

-0.22 (-0.43%)

USD 108.20B
SXR8:F iShares Core S&P 500 UCITS ETF..

-1.06 (-0.20%)

USD 93.32B
ZPDJ:F SPDR® MSCI Japan UCITS ETF

N/A

USD 86.92B
SXRZ:F iShares VII PLC - iShares Nikk..

-3.05 (-1.31%)

USD 53.24B
VUAA:F Vanguard S&P 500 UCITS Acc

+0.14 (+0.14%)

USD 51.63B
VUSA:F Vanguard Funds Public Limited ..

N/A

USD 51.63B
XDNY:F Xtrackers MSCI Japan ESG Scree..

-0.23 (-1.56%)

USD 51.19B
XJSE:F Xtrackers II - Japan Governmen..

-0.07 (-0.91%)

USD 41.09B
0ZC:F Zscaler Inc

-0.22 (-0.14%)

USD 37.92B

ETFs Containing XDWL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.23% 76% C+ 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.23% 73% C 61% D-
Trailing 12 Months  
Capital Gain 19.67% 73% C 71% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 19.67% 71% C- 62% D
Trailing 5 Years  
Capital Gain 62.42% 81% B- 77% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 62.42% 81% B- 63% D
Average Annual (5 Year Horizon)  
Capital Gain 11.58% 79% B- 73% C
Dividend Return 11.58% 77% C+ 66% D+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 13.57% 50% F 80% B-
Risk Adjusted Return 85.35% 92% A 93% A
Market Capitalization 1.13B 74% C 60% D-

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike